Breadcrumb Home investors intimation stock exchanges Intimation to stock Exchanges Quick Explore Corporate Governance Shareholding Pattern Investor contact Year 2026-20272025-20262024-20252023-20242022-20232021-20222020-20212019-20202018-20192017-20182016-20172015-20162014-20152013-20142012-20132011-20122010-2011 Apply Intimation to Stock Exchange for 2026-2027 NCLT Interim Order on Scheme of Amalgamation of Inzpera Healthsciences Limited with Cipla Limited 19th Aug 2026 ESG Rating assigned by SES ESG Research Private Limited and NSE Sustainability Ratings & Analytics Limited 11th Aug 2026 Update on USFDA inspection at InvaGen manufacturing facility in Hauppauge, Long Island, New York, USA 04th Aug 2026 Allotment of 7,850 equity shares under ESOS 2013-A Scheme and the Cipla ESAR Scheme 2021 of the Company 31st Jul 2026 Cipla Receives U.S. FDA Approval for Generic Advair Diskus® 27th Jul 2026 Q1 FY27 Earnings conference call recording 23rd Jul 2026 Disclosure relating to the change in CFO. 23rd Jul 2026 Disclosure relating to the change in SMP 23rd Jul 2026 Grant Of Stock Options and Employee Stock Appreciation Rights 23rd Jul 2026 Change in the Key Managerial Personnels (KMPs) and Officers authorised under Regulation 30(5) of the SEBI Listing Regulations. 23rd Jul 2026 Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Next page › Last page last BSE and NSE Quotes by TradingView The displayed data is not in real time and may have streaming delays.
